Small Cap Feast
Small Cap Feast – 08 March 2017
Dish of the Day:
No AIM Joiners Today
No AIM Joiners Today
Off the Menu:
No AIM Leavers Today
No AIM Leavers Today
What’s Cooking in the IPO Kitchen?
Ocelot Partners—Intention to join the Standard List. Has raised $425m at $10 for acquisition purposes. Focussing on European TMT prospects
BiopPharmma Credit—Targeting $300m + raise on LSE. “This investment trust will give investors access to debt investments tied to the fast growing life sciences industry, offering predictable cash flows over a sustained period of time.” Admission due 27 Mar.
Tufton Oceanic Assets –The Company intends to invest in a diversified portfolio of second hand commercial sea-going vessels where the Investment Manager believes that an attractive opportunity exists in shipping. $150m raise. Admission 3 April.
Europa Oil & Gas Hldgs(EOG.L) 5.87p £14.39m
The UK and Ireland focussed exploration, development and production company, has signed a Farm-Out Agreement with a wholly owned subsidiary of leading operator Cairn Energy PLC Group (LSE:CNE), Capricorn, in relation to a 70% interest in and operatorship of Licensing Option 16/19 (‘LO 16/19’ or the ‘Licence’). Europa will retain a 30% interest in the Licence, which is located on the Western flank of the South Porcupine Basin, offshore Ireland. Capricorn to fund a US$6 million work programme, which includes the acquisition, processing, and interpretation of 3D seismic, to acquire a 70% interest in and operatorship of LO 16/19. 3D seismic to be acquired in 2017 and processed product will be delivered in 2018. Europa will fund its 30% interest in LO 16/19 on completion of the fully carried work programme.
Anpario (ANP.L) 300p £68.6m
FYDec16 results from the international producer and distributor of natural feed additives for animal health, hygiene and nutrition. 10% rise in adjusted net profit from continuing operations to £3.4m. 4% increase in sales revenue to £24.3m. 10% increase in the proposed final dividend to 5.5p per share. Cash balances of £11.1m at year end. Significant strategic progress achieved under new CEO including a new strategy for growth and newly aligned organisational structure. “Trading in the new year has started well, maintaining the momentum of the second half of 2016.” “Our strong balance sheet gives Anpario the platform from which to make selective earnings enhancing acquisitions to strengthen its market position and sensibly broaden its product range with scientifically proven products.” FY17E rev £26.29m and PBT of £4.25m. 19x PE.
Genedrive (GDR.L) 41.5p £7.76m
The near patient molecular diagnostics company, has successfully completed clinical validation studies to support a submission for CE regulatory approval of its Genedrive® HCV ID Kit (Hepatitis C). The studies, performed at Institut Pasteur, Paris, and Queen’s Medical Centre, Nottingham, demonstrated an overall sensitivity of greater than 99% and specificity of 100% over a 955 sample cohort, comparing the test to the Abbott Molecular RealTime HCV Viral Load Assay. The Company anticipates submission for CE certification under the EU Medical Devices Directive for Genedrive® HCV ID Kit by the end of March 2017. “The Genedrive® HCV ID Kit is a rapid and simple to use point of need test that would enable real-time treatment and management of chronic HCV patients in decentralised settings.”
Attraqt (ATQT.L) 44p £11.85m
The provider of onsite search, online merchandising and eCommerce personalisation technology, has completed its acquisition of Fredhopper BV. Fredhopper is a cloud-based provider of onsite search, navigation, recommendation and visual merchandising solutions through a global SaaS platform, and has a large recurring revenue base. This represents a transformational opportunity which brings critical mass to ATTRAQT – the Enlarged Group has a strong presence in the UK, US and Continental Europe with approximately 250 clients. £27.8m raised at 25p to fund the acquisition with the balance to fund the integration of the two businesses, investment into sales and marketing, customer support and on-going product development and general working capital for the Enlarged Group.
LoopUp Group (LOOP.L) 161.5p £66.17m
FYDec16 results from the premium remote meetings company. LoopUp Revenue grew 39% in FY2016, to £12.8m an increase in growth rate from 36% in FY2015 and 37% in FY2014. FY2016 EBITDA increased by 102% to £2.1 million . Net cash of £2.2m. IPO in August 2016 raising £8.5m. “Looking ahead into 2017, we continue to see strong demand for the LoopUp product and are confident in our ability to deliver further growth.” Maiden operating profit of £0.4m. EPS of 0.6p vs consensus of 1.26p. FYDec17E rev of £17.1m and PBT of £2.9m.
Tyman (TYMN.L) 302.75p £539.02m
FYDec2016 results from the international supplier of engineered components to the door and window industry. Revenue +29% to £457.6m and underlying EPS +32% to 25.41p. Divi +20% to 10.5p. Net debt £176.7m. Integration of the three acquisitions completed in the year now well advanced. Current year has started positively and in line with expectations across each of the Divisions. FYDec17E rev of £512.36m and PBT of £63.56m. PE11.4x. Yield 3.7%.
WANdisco (WAND.L) 477.5p £167.74m
FYDec16 results from the Active Data Replication™ specialist. Total bookings for the year increased 72% to $15.5m. Big Data and Cloud bookings rose 184% to $7.1m. Cash overheads were reduced by $11.2m to $23.4m . Adjusted EBITDA loss was more than halved to $7.5m. Cash at year-end of $7.6m. Cash burn reduced to $0.2m in Q4 2016. Debt-free as at 31 December 2016. ‘Whilst the timing of contract wins remains variable, we are confident that WANdisco enters 2017 on a strengthened operational footing and is moving closer to cash flow break-even. With a compelling product for Big Data in the Cloud, increasing engagement of our channel partners and a well-established Source Code Management product, we expect continued improvement in our results for 2017.’
Milamber Ventures (NEX:MLVP) 12.5p £0.8m
The incubator working with a number of dynamic fast growth companies to help them through their business development and funding activities, it has signed up a number of new Portfolio Companies in the UK and the US, bringing the total number of companies it works with to 25. See release for details of individual companies across a range of industries. An earlier GM requisition by Mark Bernard Battles has been suspended now that discussions have been entered into with Mr Battles, who had been the subject of a 6 February Board meeting regarding his directorship.
Ace Liberty and Stone* (NEX:ALSP) 5p £49.1m
The Company’s General Meeting has been convened for 31 March. The purpose of the General Meeting is to seek to consolidate the shares (25 for 1) order to have a number of shares in issue which is more appropriate for a company of the Company’s size. The Company believes, due to the fact Ace is now an established business with many years of trading, the Company is no longer a “penny stock” and a consolidation should result in a more suitable trading price. Moreover, the Company believes that having a smaller and more streamlined shareholding which is more in keeping with other NEX Exchange Growth Market companies, will ensure the Company remains attractive to outside investors as the Company seeks to grow and develop the business over the coming year.
OptiBiotix Health (OPTI.L) 76p £59.69m
The life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, has entered into a manufacturing and supply agreement with Sacco S.r.l. The agreement grants Sacco an exclusive licence to manufacture and supply OptiBiotix’s cholesterol reducing strain, LPLDL®, in Europe in return for 50% of the profit with a minimum price per kilogramme to secure against discounting. To be supplied as a raw ingredient subject to potential separate licensing agreements. Discussions are progressing with corporate partners for the manufacture and supply of products containing LPLDL® in the US, Asian and other international markets.” FYJul16E revs of £0.3m and pre-tax loss of £1.2m.
0203 764 2344
*A corporate client of Hybridan LLP
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email firstname.lastname@example.org with “unsubscribe me”.